Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population

Table 3 Concordance in the treatment of hepatocellular carcinoma proposed by the Hong Kong liver cancer system and Barcelona clinic liver cancer classification in a South American population

Variables1	BCLC-0 (ablation, LR or LT)	BCLC-A (ablation, LR or LT)	BCLC-B (TACE)	BCLC-C (SOR)	BCLC-D (ST)
HKLC-I (ablation, LR or LT)	25 (100%)	129 (52.4%)	24 (22.4%)
HKLC-IIA (ablation, LR or LT)		84 (34.1%)	11 (10.3%)
HKLC-IIB (LR)		25 (10.2%)	22 (20.6%)
HKLC-IIIA (TACE)		8 (3.3%)	20 (18.7%)	1 (1.3%)
HKLC-IIIB (TACE)			30 (28.0%)
HKLC-IVA (SOR)				32 (42.1%)
HKLC-IVB (SOR or ST)				43 (56.6%)
HKLC-VA (LT)					38 (58.5%)
HKLC-VB (ST)					27 (41.5%)

¹Variables described by frequency (%). The highlighted square in the table means that there was agreement in the treatment of HCC proposed by the HKLC system and BCLC classification. BCLC: Barcelona clinic liver cancer; HCC: Hepatocellular carcinoma; HKLC: Hong Kong liver cancer; LR: Liver resection; LT: Liver transplantation; ST: Symptomatic treatment; SOR: Sorafenib; TACE: Transarterial chemoembolization.